June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

May 11, 2016May 11, 2016

Study Finds 2 Types of Psoriasis, Palmoplantar Pustulosis and Palmoplantar Pustular, Are Related Ills

News

Data from a gene expression array shows that palmoplantar postulosis (PPP) and palmoplantar pustular psoriasis (PPPP) are genetically similar diseases but different from psoriasis vulgaris, the most common form of psoriasis. ... Read more

May 6, 2016May 6, 2016

Sun Pharma Reports Positive Phase 3 Results for Plaque Psoriasis Treatment

News

Sun Pharma recently reported that two pivotal Phase 3 studies, assessing the safety and efficacy of the IL-23p19 inhibitor antibody tildrakizumab (MK-3222) in patients with moderate-to-severe plaque psoriasis, met their primary endpoints ... Read more

May 5, 2016May 5, 2016

Eli Lilly Announces Its Psoriasis Treatment, Taltz, Is Now Available in the US

News

Eli Lilly and Company has announced that Taltz injection 80 mg/mL is now available by prescription order in the U.S. for the treatment of moderate-to-severe plaque psoriasis. Taltz (ixekizumab) was approved ... Read more

May 4, 2016May 4, 2016

Possible Genetic Mechanism Links Psoriasis with Obesity, Danish Twin Study Indicates

News

A possible common genetic mechanism linking psoriasis and metabolic syndromes, including obesity, is the key finding of a recent report performed with Danish twins by a team of researchers at the University of Copenhagen in Denmark. ... Read more

May 3, 2016

Largest American Psoriasis Registry to Track Newly Approved Plaque Psoriasis Treatment Ixekizumab

News

The Corrona Psoriasis Registry, a 16-year independent registry with no ownership links to the pharmaceutical industry and the leading sponsor of registries in autoimmune diseases, and the National Psoriasis Foundation ... Read more

April 29, 2016

Study Links Psoriasis Severity to Increased Risk of Abdominal Aortic Aneurysm

News

People with psoriasis are at increased risk of developing abdominal aortic aneurysms (AAA), according to a new study published in the journal Arteriosclerosis, Thrombosis and Vascular Biology. In the study, ... Read more

April 28, 2016April 28, 2016

Phase 1 Trial for Chronic Plaque Psoriasis Treatment Launched by Exicure

News

Exicure, a company developing a new class of immunomodulatory and gene-silencing drugs including Spherical Nucleic Acid (SNA), has just announced the dosing of the first patient in its Phase 1 ... Read more

April 27, 2016April 27, 2016

New Psoriasis Treatment Strategies Spurred by Genetic Research

News

A team of researchers from the Vlaams Institute for Biotechnology (VIB) in Belgium discovered a molecular mechanism by which specific mutations in the protein coding gene CARD14 can lead to abnormal inflammation ... Read more

April 21, 2016April 21, 2016

Psoriasis Drug Trial’s ‘Database Soft Lock’ for Prurisol Announced by Cellceutix, Along with Company Updates

News

Cellceutix, a clinical stage biopharma that develops novel therapies for oncology, dermatology, anti-inflammatory, and antibiotic applications, is announcing the institution of a “Database Soft Lock” as well as key additional updates ... Read more

April 18, 2016April 18, 2016

Laser Therapy for Psoriasis Shows No Indication of Koebner Effect, According to Study

News

A recent research study demonstrated that people suffering from plaque psoriasis who received laser treatment did not show evidence of subsequent koebnerization. The research study, “Absence of Koebnerization Following Ablative and ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata